These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The biologics of ulcerative colitis. Macaluso FS; Renna S; Orlando A; Cottone M Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557 [TBL] [Abstract][Full Text] [Related]
26. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis. Hagan M; Cross RK Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250 [TBL] [Abstract][Full Text] [Related]
29. Vedolizumab for the treatment of ulcerative colitis. Stallmach A; Schmidt C; Teich N Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993 [TBL] [Abstract][Full Text] [Related]
30. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Feagan BG; Schreiber S; Wolf DC; Axler JL; Kaviya A; James A; Curtis RI; Geransar P; Stallmach A; Ehehalt R; Bokemeyer B; Khalid JM; O'Byrne S Inflamm Bowel Dis; 2019 May; 25(6):1028-1035. PubMed ID: 30365009 [TBL] [Abstract][Full Text] [Related]
31. Should we use vedolizumab as mono or combo therapy in ulcerative colitis? Hedin C; Halfvarson J Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935 [TBL] [Abstract][Full Text] [Related]
32. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652 [TBL] [Abstract][Full Text] [Related]
33. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. Tsai HH; Black C Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457 [TBL] [Abstract][Full Text] [Related]
34. Vedolizumab for the treatment of ulcerative colitis. Shahidi N; Bressler B; Panaccione R Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005 [TBL] [Abstract][Full Text] [Related]
36. Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center. Hoffmann P; Krisam J; Stremmel W; Gauss A Dig Dis; 2019; 37(1):33-44. PubMed ID: 30134234 [TBL] [Abstract][Full Text] [Related]
37. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? D'Amico F; Danese S; Peyrin-Biroulet L Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748 [No Abstract] [Full Text] [Related]
39. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. Cohen RD; Bhayat F; Blake A; Travis S J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340 [TBL] [Abstract][Full Text] [Related]
40. Current and emerging biologics for ulcerative colitis. Park SC; Jeen YT Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]